Preventing Adverse Drug Events With PatientSite

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

800 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-04-30

Study Completion Date

2004-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study to better understand the nature and extent of adverse drug events (ADEs), defined as injuries due to prescription medications, in primary care. We will study whether PatientSite (an internet-based communication program for patients and health care providers) can improve clinicians' ability to detect adverse drug events among primary care patients and to mitigate the consequences by sending electronic queries to patients after they receive new medication prescriptions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Improving Safety By Computerizing Outpatient Prescribing

NCT00235027

Impact of Electronic Prescribing on Medication Safety

COMPLETED NA

Information Systems-enabled Outreach Program for Adverse Drug Events

NCT02059044

Adverse Drug Events

COMPLETED NA

Medication Reconciliation in Comparison to an Extensive Medication Safety Check

NCT02413957

Elderly Adverse Drug Event

COMPLETED NA

Improving Safety by Basic Computerizing Outpatient Prescribing

NCT01091038

Adverse Drug Events

COMPLETED PHASE2/PHASE3

Prevention of Adverse Drug Events (ADEs) in Hospitalised Older Patients

NCT01467050

Adverse Drug Reaction

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* A drug safety module called MedCheck was developed for PatientSite. This allows physicians to query patients automatically 10 days after they receive a new prescription asking them questions about their new prescription. In this study new enhancements will be tested.
* Participants will be assigned at random to the intervention group or control group. The intervention group will receive a single electronic PatientSite message asking them questions about the new prescription which is then forwarded to their physician. The control group will receive a generic message about medication safety.
* To identify adverse drug events, a telephone survey and medical record review will be conducted of patients in the intervention group and controls.
* This study will run for 12 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adverse Drug Event

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MedCheck

Electronic medication safety queries via PatientSite portal

Group Type EXPERIMENTAL

Medcheck message

Intervention Type OTHER

Participants selected at random will receive one email message asking them questions about their prescription which will be forwarded to their physician

Usual care

No electronic medication safety messages via PatientSite portal

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medcheck message

Participants selected at random will receive one email message asking them questions about their prescription which will be forwarded to their physician

Intervention Type OTHER